Breakthrough in Cancer Vaccines: Nanovesicles Loaded with Tyrosine Kinase Inhibitors Boost Efficacy

Researchers from Soochow University have made a significant discovery in the field of cancer vaccines, detailing a novel strategy to enhance the efficacy of immunotherapy. By developing a nanovesicle-based approach, they have found that loading tyrosine kinase inhibitors (TKIs) into these tiny vesicles can increase Major-Histocompatibility-Complex I (MHC I) expression on tumor cells, effectively improving the cancer-fighting ability of vaccines.

Key Takeaways:

• The study, published in Frontiers in Immunology, demonstrates that nanovesicles loaded with TKIs, such as Sunitinib and Sorafenib, can upregulate MHC I expression on tumor cells, making them more recognizable to the immune system.
• The combination of these nanovesicles with whole-tumor-antigen-loaded nanovaccines elicited a synergistic antitumor effect in breast cancer and melanoma mouse models.
• The tumors in treated mice grew more slowly, and the survival times of these mice were significantly prolonged.
• The research suggests that activating the IFNg/STAT1 pathway using TKIs can improve MHC I expression, leading to increased tumor-specific T cell activation and immune-mediated tumor clearance.
• This combinatorial approach provides a promising strategy to overcome immune evasion and enhance the therapeutic outcomes of cancer vaccine-based immunotherapy.

Statistics:

• The study utilized two TKIs, Sunitinib and Sorafenib, which were encapsulated into redox-responsive nanovesicles respectively (SUN-KD10 or SOR-KD10).
• The nanovesicles demonstrated favorable tumor-targeting capabilities in the tumor microenvironment.
• The combination of nanovesicles with whole-tumor-antigen-loaded nanovaccines resulted in a 40% decrease in tumor growth and a significant prolongation of survival times in both breast cancer and melanoma mouse models.

Sources:

• Elevating MHC I expression on tumor cells by nanovesicles loading tyrosine kinase inhibitors can improve the efficacy of cancer vaccines. Frontiers in Immunology, 2025;16:1653533.
• NewsRx. Studies from Soochow University Reveal New Findings on Cancer Vaccines (Elevating MHC I expression on tumor cells by nanovesicles loading tyrosine kinase inhibitors can improve the efficacy of cancer vaccines). Vaccine Weekly. October 15, 2025; p 130.